IMpower133: patient-reported outcomes (PROs) in a ph1/3 study of first-line (1L) atezolizumab (atezo) plus carboplatin plus etoposide (CP/ET) in extensive-stage SCLC (ES-SCLC)
Califano, Raffaele Kazarnowicz, A Karaseva, N Sanchez, A Liu, V Horn, L Quach, C Yu, W Kabbinavar, F Lam, S
Califano, Raffaele
Kazarnowicz, A
Karaseva, N
Sanchez, A
Liu, V
Horn, L
Quach, C
Yu, W
Kabbinavar, F
Lam, S
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2018
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Califano R, Ka?arnowicz A, Karaseva N, Sánchez A, Liu SV, Horn L, et al. IMpower133: Patient-reported outcomes (PROs) in a ph1/3 study of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide (CP/ET) in extensive-stage SCLC (ES-SCLC). Ann Oncol. 2018;29(suppl_10):17.